

## Arkansas Medicaid DRC Meeting Minutes

<b>Date / Time:</b>	May 11, 2022 9:03 – 10:26 AM Central		<b>Location:</b>	ZOOM webinar	
<b>Chair:</b>	Cindi Pearson, Pharm.D.		<b>Reports:</b>	Lynn Boudreaux, Pharm.D. Magellan	
		<b>Panelist (voting members)</b>		<b>Panelist (non-voting members)</b>	<b>Organization</b>
		X Melissa Max, Pharm.D.		X Barry Fielder, Pharm.D.	ATC
		X Laurence Miller, M.D.		X Phuong Luu, Pharm.D.	Empower
		X Daniel Pace, M.D.		X Lauren Jimerson, Pharm.D.	Summit
		Chad Rodgers, M.D.		X Turkesia Robertson-Jones, Pharm. D.	CareSource
		Vacant Pharm.D. position		Elizabeth Pitman	DHS Director
		Vacant Pharm.D. position		X Cindi Pearson, Pharm.D.	DHS, DRC Chair
		Vacant Pharm.D. position		X Cynthia Neuhofel, Pharm.D.	DHS pharmacy
				Karen Evans, P.D.	Magellan
				X Lynn Boudreaux, Pharm.D.	Magellan
				X Lesley Irons, Pharm.D.	Magellan
<b>Call to order</b>	Meeting held virtually by ZOOM webinar. A quorum was present, and the chair called the meeting to order at 9:03am.				
<b>Public comments</b>	<ol style="list-style-type: none"> <li>1. Jenna McGowan, Pharm.D.—AbbVie for Vraylar®</li> <li>2. Timothy Birner, Pharm.D.—Alkermes for Lybalvi®</li> <li>3. Madeline Shurtleff, Pharm.D.—Otsuka for Rexulti®</li> </ol>				
<b>Announcements</b>	<ol style="list-style-type: none"> <li>1. There were no conflicts of interest by any voting committee member, Dr. Pearson, or Dr. Boudreaux.</li> <li>2. Format for the August 2022 meeting has not been established</li> <li>3. Preferred Drug List changes effective April 1, 2022</li> <li>4. DUR PA manual review drugs from April 20, 2022 DUR meeting</li> <li>5. POS edits from April 20, 2022 DUR meeting</li> <li>6. Chair provided the schedule of future DRC meeting dates</li> </ol>				
<b>Minutes</b>	Motion to approve February 2022 meeting minutes as presented was made by Dr. Pace, seconded by Dr. Miller. All voting members present voted to approve the minutes as written. Motion passed.				
<b>Class Reviews</b>	<ol style="list-style-type: none"> <li>1. <b>ANTIPSYCHOTICS</b>  This review is a renewal for the antipsychotic agents’ class. Chair provided current PA requirements for all agents in the class. After a question from an attendee, Dr. Pearson clarified that informed consent for children may be done verbally if the caregiver cannot be present to sign the consent form themselves. Dr. Boudreaux presented a PowerPoint with the following information. <ol style="list-style-type: none"> <li>a) FDA approved indications for first and second generation antipsychotics</li> <li>b) Overview of schizophrenia including DSM-V criteria</li> <li>c) Overview of bipolar disorder including DSM-V criteria</li> <li>d) Pharmacology</li> <li>e) American Psychiatric Association 2020 guidelines for schizophrenia and bipolar</li> <li>f) World Federation of Societies of Biological Psychiatry guidance on schizophrenia 2015</li> <li>g) American Academy of Child and Adolescent Psychiatry recommendations</li> <li>h) International College of Neuropsychopharmacology 2017 guidelines for bipolar</li> </ol> </li> </ol>				

## Arkansas Medicaid DRC Meeting Minutes

- i) Indian Journal of Psychiatry guidelines for bipolar 2017
- j) Claims summary from 1/1/2021-12/31/2021

### **DISCUSSION:**

Dr. Max wanted options with less weight gain, like Rexulti. Dr. Miller stated we should be considering clinical information not cost in this meeting. Dr. Miller wants this committee to consider other nonpreferred options. Dr. Miller stated that chlorpromazine has been nonpreferred due to cost, but we are seeing an increase in the number of adults being prescribed it. Latuda we often see for pregnant women, because it has a REMS program which is important to consider. Vraylar is important to consider due to its multiple indications. Caplyta is being prescribed for a number of patients that have failed other medications but not first line. Dr. Miller wants the committee to consider the indications for the medications. Dr. Max stated that if the efficacy is the same, we should consider Rexulti due to the more positive effects on weight. Dr. Pearson asked if there was a motion being made based on the conversation or should these recommendations be reviewed based on the cost committee recommendations. Dr. Max made the motion to approve Rexulti as a preferred option for a second generation antipsychotic. Dr. Miller made the motion to add Latuda, Caplyta, and Vraylar as preferred options. Dr. Pearson stated Dr. Miller will be consulted after the input of the cost committee.

### **ACTION:**

Motion was made by Dr. Miller to add multiple non-preferred medications to the preferred list; seconded by Dr. Max; Approved by Dr. Pace. Motion passed.

## **2. BOWEL PREP AGENTS**

This review is a renewal for the bowel prep agents' class. Chair provided general information on colonoscopies. Dr. Boudreaux presented a PowerPoint with the following information.

- a) FDA approved indications for bowel prep agents
- b) Dosing regimens
- c) Efficacy and safety comparison
- d) Claims summary from 1/1/2021-12/31/2021

### **DISCUSSION:**

Dr. Pearson asked Dr. Boudreaux to pull up the claims summary slide. Dr. Pearson stated we have a pretty good selection of preferred products currently. If the staff gets a PA request for a nonpreferred option, the patient's overall health is taken into consideration. Dr. Pearson made the recommendation to keep the current preferred list as long as that is recommended by the cost committee as well.

### **ACTION:**

Motion was made by Dr. Max to continue the current preferred list; seconded by Dr. Miller; approved by Dr. Pace. Motion passed.

## **3. CYSTINE DEPLETING AGENTS/PENICILLAMINE AGENTS**

This review is a renewal for the cystine depleting agents' class. Chair provided indications for each product and information on Wilson's disease and cystinuria. Dr. Boudreaux presented a PowerPoint with the following information.

- a) FDA approved indications

## Arkansas Medicaid DRC Meeting Minutes

	<ul style="list-style-type: none"> <li>b) Overview on cystinuria</li> <li>c) UpToDate guideline consensus on treatment</li> <li>d) Claims summary from 1/1/2021-12/31/2021</li> </ul> <p><b>DISCUSSION:</b> Dr. Max asked if this class would follow the same procedure for requesting a nonpreferred option. Dr. Pearson confirmed. The other 2 members agreed that this class was fine.</p> <p><b>ACTION:</b> Motion was made by Dr. Max to continue the current preferred list; seconded by Dr. Miller; Approved by Dr. Pace. Motion passed.</p> <p><b>4. PROTON PUMP INHIBITORS</b> This review is a renewal for the proton pump inhibitors class. Chair provided DUR Board criteria for the class. Dr. Boudreaux presented a PowerPoint with the following information.</p> <ul style="list-style-type: none"> <li>a) FDA approved indications</li> <li>b) Overview of the mechanism for PPIs</li> <li>c) Summary of uses for PPIs</li> <li>d) Long term effects for PPIs</li> <li>e) ACG clinical guideline for the diagnosis and management of GERD 2022</li> <li>f) Evidence based medicine</li> <li>g) Claims summary from 1/1/2021-12/31/2021</li> </ul> <p><b>DISCUSSION:</b> Dr. Pearson stated that the current POS criteria would still be in place. Dr. Pearson stated that since the products have comparable efficacy we can continue with omeprazole and pantoprazole as preferred options if found to be economically best option for the state. Dr. Pearson also suggested to keep a formulation for children with easier access. Dr. Max asked if there was a suspension for lansoprazole. Dr. Boudreaux stated that there is a first suspension for lansoprazole which is a compounding type kit that we do not cover. Nexium packet for suspension is the current preferred option for children and those designated as NPO and will process at POS without a PA for those patients. Dr. Pearson recommended to defer to the cost committee on the products for children since the efficacy is similar.</p> <p><b>ACTION:</b> Motion made by Dr. Pace to continue the current PDL list with the ODT/suspension product based on overall cost; seconded by Dr. Max; approved by Dr. Pace. Motion passed.</p>
<b>Comment from Chair</b>	Dr. Pearson wanted to remind the committee that their recommendations will be taken to the state along with the recommendations by the cost committee. Those recommendations will be combined and reviewed by the state.
<b>Adjourn</b>	Meeting adjourned at 10:26am.